Rapamycin has shown promise in reversing PTPN11 mutant hypertrophic cardiomyopathy in mouse models by inhibiting the mTOR pathway; however, its application in human subjects requires further clinical validation (31, 32). Here, MTOR is linked to hypertrophic cardiomyopathy.